



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|--|-------------|----------------------|-------------------------|------------------|
| 10/050,188 | 01/14/2002 | Tracy L. Ferea | 07414.0055-00000 | 6282 |
| 7590 04/08/2004 | | | EXAMINER | |
| Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. 1300 I Street, N.W. Washington, DC 20005-3315 | | | RILEY, JEZIA | |
| | | | ART UNIT | PAPER NUMBER |
| | | | 1637 | |
| | | | DATE MAILED: 04/08/2004 | 1 |

Please find below and/or attached an Office communication concerning this application or proceeding.

| | Application No. | Applicant(s) |
|---|---|---|
| | 10/050,188 | FEREA ET AL. |
| Office Action Summary | Examiner | Art Unit |
| | Jezia Riley | 1637 |
| The MAILING DATE of this communication ap Period for Reply | pears on the cover sheet | with the correspondence address |
| A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a rep If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailine earned patent term adjustment. See 37 CFR 1.704(b). | 136(a). In no event, however, may ly within the statutory minimum of the will apply and will expire SIX (6) MG, cause the application to become | a reply be timely filed nirty (30) days will be considered timely. DNTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133). |
| Status | | |
| 1) Responsive to communication(s) filed on <u>resp</u> 2a) This action is FINAL. 2b) This 3) Since this application is in condition for alloward closed in accordance with the practice under the pra | s action is non-final. | • |
| Disposition of Claims | | |
| 4) ⊠ Claim(s) <u>1-32</u> is/are pending in the application 4a) Of the above claim(s) <u>11-25</u> is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ⊠ Claim(s) <u>1-10 and 26-32</u> is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ⊠ Claim(s) <u>1-32</u> are subject to restriction and/or | wn from consideration. | |
| Application Papers | | |
| 9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomposed and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 11. | epted or b) objected to drawing(s) be held in abeya tion is required if the drawin | g(s) is objected to. See 37 CFR 1.121(d). |
| Priority under 35 U.S.C. § 119 | | |
| 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list | s have been received. s have been received in rity documents have bee u (PCT Rule 17.2(a)). | Application No n received in this National Stage |
| Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date | Paper No | Summary (PTO-413) (s)/Mail Date Informal Patent Application (PTO-152) |

DETAILED ACTION

Response to Remarks

- 1. Applicants' arguments and amendments, filed on 3/15/2004, have been approved and entered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either newly applied or reiterated. They constitute the complete set presently being applied to the instant application.
- 2. Applicant's request for reconsideration of the finality of the rejection of the last Office action is persuasive and, therefore, the finality of that action is withdrawn.

Claim Rejections - 35 USC § 103

- 3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

2000

Application/Control Number: 10/050,188

Art Unit: 1637

4. Claims 1-10, 26-32 rejected under 35 U.S.C. 103(a) as being unpatentable over Drmanac (US6,309,824) in view of Gingeras et al. (US6,228,575).

Drmanac provides a method for detecting a target nucleic acid species including the steps of providing an array of probes affixed to a substrate and a plurality of labeled probes wherein each labeled probe is selected to have a first nucleic acid sequence which is complementary to a first portion of a target nucleic acid and wherein the nucleic acid sequence of at least one probe affixed to the substrate is complementary to a second portion of the nucleic acid sequence of the target, the second portion being adjacent to the first portion; applying a target nucleic acid to the array under suitable conditions for hybridization of probe sequences to complementary sequences; introducing a labeled probe to the array; hybridizing a probe affixed to the substrate to the target nucleic acid; hybridizing the labeled probe to the target nucleic acid; affixing the labeled probe to an adjacently hybridized probe in the array; and detecting the labeled probe affixed to the probe in the array. The invention also provides a method of determining expression of a member of a set of partially or completely sequenced genes in a cell type, a tissue or a tissue mixture comprising the steps of: defining pairs of fixed and labeled probes specific for the sequenced gene; hybridizing unlabeled nucleic acid sample and corresponding labeled probes to one or more arrays of fixed probes; forming covalent bonds between adjacent hybridized labeled and fixed probes which is viewed to be inclusive of instant claim 5 for example; removing unligated

Application/Control Number: 10/050,188

Art Unit: 1637

probes; and determining the presence of the sequenced gene by detection of labeled probes bound to prespecified locations in the array. The 5' and 3' ends of sequence nuclei may be overlapped to generate longer stretches of sequence. Where ambiguities arise in sequence assembly due to the availability of alternative proper overlaps with probes or sequence nuclei, hybridization with longer probes spanning the site of overlap alternatives, competitive hybridization, ligation of alternative end to end pairs of probes spanning the site of ambiguity or single pass gel analysis (to provide an unambiguous framework for sequence assembly) may be used. Oligonucleotide probes may be labeled with, for example, radioactive labels, non-radioactive isotopes; or fluorophores. Oligonucleotide probes may be labeled with fluorescent dyes, chemiluminescent systems, radioactive labels (e.g. .sup.35 S, .sup.3 H, .sup.32 P or .sup.33 P) or with isotopes detectable by mass spectrometry. In the implementation of a multiple label color scheme (i.e., multiplexing), two to six probes, each having a different label such as a different fluorescent dye, may be used as a pool, thereby reducing the number of hybridization cycles and shortening the sequencing process. Which is viewed to be inclusive of the instant claims 27-29.

Drmanac does not disclose the limitation "wherein at least one of the feature does not comprise a control specific probe". But it would have been obvious at the time the invention was made to select regions or features on an array that does not comprise a control specific probe, since such feature is disclosed in the array methodology as shown by Gingeras et al. Gingeras specifically says that for "conceptual simplicity, the probes in a set are usually arranged in order of the sequence in a lane across the chip,

Page 5

Application/Control Number: 10/050,188

Art Unit: 1637

although this arrangement is not required. For example, the probes can be randomly distributed on the chip. A lane contains a series of overlapping probes, which represent or tile across, the selected reference sequence (see FIG. 3). The components of the four sets of probes are usually laid down in four parallel lanes, collectively constituting a row in the horizontal direction and a series of 4-member columns in the vertical direction. Corresponding probes from the four probe sets (i.e., complementary to the same subsequence of the reference sequence) occupy a column. Each probe in a lane usually differs from its predecessor in the lane by the omission of a base at one end and the inclusion of additional base at the other end as shown in FIG. 3. However, this orderly progression of probes can be interrupted by the inclusion of control probes or omission of probes in certain columns of the array. Such columns serve as controls to orient the chip, or gauge the background, which can include target sequence nonspecifically bound to the chip. (col.16).

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jezia Riley whose telephone number is 571-272-0786. The examiner can normally be reached on 9:30AM - 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 10/050,188

Art Unit: 1637

Page 6

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Monday, April 05, 2004

JEZIA RILEY PRIMARY EXAMINER